PRESS RELEASE: Costly Polytherapy and an Aging Population will Fuel Steady Expansion of the Parkinson's Disease Market

[Murray Charters <mcharters@xxxxxxxxxxxxxx>]

PRESS RELEASE: Costly Polytherapy and an Aging Population will Fuel Steady 
Expansion of the Parkinson's Disease Market
Monday February 23, 8:06 am ET

Novartis/Orion's Comtan Franchise Set To Grow Fivefold Over the Next Ten Years 
According to a New Study from Decision
Resources

WALTHAM, Mass., Feb. 23 /PRNewswire/ -- Decision Resources, Inc., one of the 
world's leading research and advisory
firms focusing on pharmaceutical and health care issues, finds that the 
Parkinson's disease (PD) market will grow
steadily in the next ten years as populations age and polytherapy becomes the 
norm in both the early and more advanced
stages of the disease.

A new study entitled Parkinson's Disease finds that the newer, more expensive 
therapies such as dopamine agonists will
boost the number of PD patients taking polytherapy, thus increasing the overall 
drug market's value.

"Novel therapies designed to improve patients' responses to levodopa will 
greatly expand the PD market over the next
decade," said Tricia Nagle, analyst at Decision Resources. "Also fueling this 
sector will be continued growth by
current market leaders, including Novartis/Orion's Comtan, GlaxoSmithKline's 
Requip, and Pfizer/Boehringer Ingelheim's
Mirapex/Sifrol. Overall drug sales for PD in the major markets in 2012 will 
more than double 2002 sales."

About Parkinson's Disease

The chronic, progressive nature of PD and the fact that no currently available 
treatments slow or stop the disease's
progression make it an attractive target for drug development. Moreover, an 
ever-growing elderly population that will
lead to a steadily increasing number of PD sufferers over the next decade 
renders the PD market a highly lucrative area
of opportunity.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assess a host of market- impacting 
factors and analyzes the commercial
outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc.,  is a world leader in 
research publications, advisory
services, and consulting designed to help clients shape strategy, allocate 
resources, and master their chosen markets.

All company, brand, or product names contained in this document may be 
trademarks or registered trademarks of their
respective holders.

For more information, contact:

Elizabeth Marshall
Decision Resources, Inc.
781-296-2563
emarshall@xxxxxxxxxxxxxx

Source: Decision Resources, Inc.

SOURCE: Yahoo News (press release)


* * *

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:listserv@xxxxxxxxxxxxxxxxxxxx
In the body of the message put: signoff parkinsn